{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-132569","form_type":"8-K","ticker":"NVAX","cik":"0001000694","company_name":"NOVAVAX INC","filed_at":"2024-12-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.289167+00:00","generated_at":"2026-05-28T22:36:38.651367+00:00","sec_items":["2.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Novavax completes $200M sale of Czech manufacturing campus to Novo Nordisk","bullets":["Total purchase price $200M; $180M cash at close, $10M paid Sept 2024, $10M escrow for 12 months.","Seller also received ~$2.6M reimbursement for operating costs between Dec 3 and closing.","Novavax sold its Bohumil, Jevany facility including land, movable assets, contracts, and employees.","Transaction closed Dec 30, 2024; Novo Nordisk Production Czech s.r.o. is the purchaser."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-132569","json":"https://secwatch.observer/filing/0001104659-24-132569.json","markdown":"https://secwatch.observer/filing/0001104659-24-132569.md","text":"https://secwatch.observer/filing/0001104659-24-132569.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000694/000110465924132569/0001104659-24-132569-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000694/000110465924132569/tm2432218d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T22:36:38.651367+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"69687a135550951a001d9c412d266896100f2785","claim":"NOVAVAX INC completed a disposition involving Novo Nordisk Production Czech s.r.o. for $200 million and the assumption by the Purchaser of liabilities (closed 2024-12-30).","evidence_excerpt":"(iii) certain employees currently providing services related to the Transferred Assets (the “Transferred Employees”). The total purchase price for the Facility was $200 million and the assumption by the Purchaser of liabilities (on a look-forward basis) pertaining to the Transferred Assets, Transferred Contracts and Transferred Employees. On the closing","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465924132569/0001104659-24-132569-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Novo Nordisk Production Czech s.r.o."},{"label":"Consideration","value":"$200 million and the assumption by the Purchaser of liabilities"},{"label":"Closing","value":"2024-12-30"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}